Compare Thomson Reuters Corp (TRI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Thomson Reuters Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Thomson Reuters Corp trades at $97 (market cap $42.12B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: Thomson Reuters Corp pays a 2.7% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Thomson Reuters Corp nearer its low. Which is the better fit depends on your goals.
| TRI | XBI | |
|---|---|---|
Market Cap | $42.12B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $173.48 | $169.55 |
52-Week Low | $76.55 | $93.43 |
Enterprise Value | $44.73B | — |
Dividend Yield | 2.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Thomson Reuters (TRI) trades at $98.81, down 6.5% recently, amid a bearish technical signal. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $0.99 per share and revenue growth of 9% year-over-year. Recent news highlights AI expansion with the launch of its proprietary LLM 'Thomson' and a cybersecurity incident affecting its case management system. Valuation ratios include a P/E of 26.03 and net income margin of 21.22%, indicating robust profitability but premium pricing.
Outlook is mixed: analyst consensus is bullish with a $113 price target, but technical weakness and cybersecurity risks pose headwinds. Investment opportunity lies in TRI's recurring revenue model and AI-driven growth, while risks include execution challenges and market sentiment shifts. The stock's current dip may offer a entry point for long-term investors focused on sustainable tech adoption.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
